Background

Evidence suggests that psoriasis might be associated with metabolic syndrome and an increased risk for cardiovascular disease.

Objective

To determine whether ustekinumab reduces systemic and vascular inflammation associated with metabolic syndrome and cardiovascular disease, measured using ¹⁸F-fluorodeoxyglucose positron emission tomography–computed tomography (¹⁸F-FDG PET/CT).

Methods

Patients with psoriasis and healthy controls underwent baseline ¹⁸F-FDG PET/CT imaging. Patients with moderate-to-severe psoriasis were treated with ustekinumab and underwent ¹⁸F-FDG PET/CT again after a Psoriasis Area and Severity Index of 75 was achieved.

Results

After a Psoriasis Area and Severity Index of 75 was achieved with ustekinumab treatment, standardized uptake values were reduced in the liver, spleen, and 5 parts of the aorta (P < .05).

Limitations

Our study does not provide outcome data concerning cardiovascular events or metabolic syndrome; it only shows surrogate markers in a limited (Korean) population.

Conclusion

Ustekinumab treatment was significantly associated with decreased systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease among patients with psoriasis.

中文翻译：

---

Ustekinumab治疗与中度至重度牛皮癣患者的全身和血管炎症减少相关：使用¹⁸ F-氟脱氧葡萄糖PET / CT的可行性研究

背景

有证据表明，牛皮癣可能与代谢综合症和心血管疾病的风险增加有关。

客观的

为确定ustekinumab是否能减轻与代谢综合征和心血管疾病相关的全身和血管炎症，可使用¹⁸ F-氟脱氧葡萄糖正电子发射断层显像-计算机断层显像（¹⁸ F-FDG PET / CT）进行测量。

方法

牛皮癣患者和健康对照者接受了¹⁸ F-FDG PET / CT基线成像。银屑病面积和严重性指数达到75后，用ustekinumab治疗中重度牛皮癣患者，并再次进行¹⁸ F-FDG PET / CT。

结果

用ustekinumab治疗后，牛皮癣面积和严重性指数达到75，肝脏，脾脏和主动脉的5个部位的标准摄取值降低（P  <.05）。

局限性

我们的研究未提供有关心血管事件或代谢综合征的结果数据；它仅显示有限（韩国）人口中的替代标记。

结论

Ustekinumab治疗与牛皮癣患者代谢综合征和心血管疾病相关的全身和血管炎症的减少显着相关。